Kintegral Advisory LLC Acquires New Holdings in Moderna, Inc. $MRNA

Kintegral Advisory LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,786 shares of the company’s stock, valued at approximately $536,000.

Several other hedge funds have also recently bought and sold shares of MRNA. Fortitude Family Office LLC boosted its holdings in shares of Moderna by 53.1% in the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock valued at $43,000 after buying an additional 77 shares during the period. Allied Private Wealth LLC acquired a new stake in shares of Moderna during the second quarter worth $30,000. Archer Investment Corp acquired a new stake in shares of Moderna during the second quarter worth $36,000. Canton Hathaway LLC bought a new stake in Moderna in the 1st quarter valued at $31,000. Finally, Frazier Financial Advisors LLC bought a new stake in Moderna in the 2nd quarter valued at $45,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Moderna

In other news, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 197,251 shares of company stock worth $33,875,904 over the last quarter. 10.80% of the stock is currently owned by insiders.

Moderna Trading Down 7.8%

NASDAQ MRNA opened at $218.01 on Friday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $242.29. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average of $156.66 and a 200-day moving average of $90.88. The company has a market cap of $87.04 billion, a PE ratio of -27.29 and a beta of 1.09.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the company earned ($2.13) earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, equities research analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MRNA. CLSA raised shares of Moderna to an “outperform” rating in a research note on Friday, August 28th. William Blair assumed coverage on Moderna in a research note on Friday, August 28th. They issued an “outperform” rating on the stock. Piper Sandler lifted their price target on Moderna from $77.00 to $167.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Finally, Bank of America upped their price objective on Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Seven research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, Moderna currently has an average rating of “Hold” and a consensus target price of $101.45.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Upcoming melanoma and other cancer-vaccine data remain the main bullish catalyst. Earlier positive results from Moderna’s personalized cancer-vaccine collaboration with Merck have increased expectations that new data could support the pipeline and help sustain the stock’s gains. Merck and Moderna cancer vaccine strategy
• Positive Sentiment: Investor interest has also been supported by strong momentum, healthcare-sector fund flows and optimism that Moderna’s pipeline could diversify the business beyond COVID-19 vaccines. Moderna rallies as money rotates into healthcare
• Neutral Sentiment: President Stephen Hoge sold a combined 78,369 shares in transactions conducted under a pre-arranged Rule 10b5-1 plan. Although the sales may weigh on sentiment, they represented only a small portion of his remaining holdings and were not discretionary trades made during the current move. Moderna insider trading filing
• Neutral Sentiment: A study comparing the stability of three mRNA vaccines in human blood may provide useful scientific context for the platform, but it does not appear to offer an immediate change to Moderna’s revenue outlook or valuation. mRNA vaccine stability study
• Negative Sentiment: Profit-taking has intensified after Moderna became one of the market’s strongest performers, with analysts cautioning that the stock’s valuation now depends heavily on successful pipeline execution. Goldman Sachs raised its target to $137 but retained a Neutral rating, leaving the target substantially below recent trading levels. Moderna valuation debate
• Negative Sentiment: The broader selloff in vaccine stocks, including declines in Novavax and BioNTech, has added sector-wide pressure. Investors are also wary of Moderna’s continuing losses and negative cash flow while awaiting the cancer-data catalyst. Vaccine-stock selloff

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.